臨床試験

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

NCT: NCT07593209 · RECRUITING

NCT識別子NCT07593209

ステータスRECRUITING

開始日2026-05-01

完了2027-12-31

SponsorFirst Hospital of China Medical University (OTHER)

First posted2026-05-18

Last updated2026-05-18

概要

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。